SyntekaBio Inc
226330
Company Profile
Business description
SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on the genome big data platform and artificial intelligence deep learning drug development platform. The company manages and analyzes genome analysis and massive biodata and genome.
Contact
187, Techno 2-ro
Yuseong-gu, Bi-dong
Yongsan-dong, Megan Techno World 2nd
Daejeon512
KORT: +82 7076630958
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2025
Employees
61
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,074.70 | 34.50 | 0.38% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,594.80 | 107.47 | 0.46% |
| Dow JONES (US) | 45,271.23 | 24.58 | -0.05% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,497.73 | 218.10 | 1.02% |
| Nikkei 225 | 42,458.37 | 519.48 | 1.24% |
| NZX 50 Index | 13,111.70 | 36.89 | 0.28% |
| S&P 500 | 6,448.26 | 32.72 | 0.51% |
| S&P/ASX 200 | 8,803.40 | 36.10 | 0.41% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |